A Randomized, Placebo Controlled Study of ABT-414 combined with Radiation and Temozolomide in Subjects with Newly Diagnosed Glioblastoma with Specific Tumor Markers

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-001166-26

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Phase 2: to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide prolongs progression free survival (PFS) in subjects with newly diagnosed GBM harboring EGFR amplificaton. Phase 3: to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide prolongs overall survival (OS) in subjects with newly diagnosed GBM harboring EGFR amplificaton


Critère d'inclusion

  • Newly diagnosed glioblastoma (GBM) or gliosarcoma